Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Efficacy and Safety of Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in the Refractory or Relapsed PTCL: A Phase 2, Single-center, Single-arm, Open Label Trial
Conditions
Interventions
Sintilimab
Chidamide
+1 more
Locations
1
China
Beijing
Beijing, Beijing Municipality, China
Start Date
April 15, 2021
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2025
Last Updated
March 9, 2021
NCT06561048
NCT06909877
NCT07270861
NCT07072221
NCT05833724
NCT06855823
Lead Sponsor
Peking University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions